Daxor Corporation (DXR)

Market Cap	59.44M +19.5%
Revenue (ttm)	26,688 -77.7%
Net Income	9.17M +1,609.7%
EPS	1.81 +1,567.3%
Shares Out	5.83M
PE Ratio	5.63
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,558
Open	10.28
Previous Close	10.24
Day's Range	10.10 - 10.30
52-Week Range	8.56 - 14.76
Beta	0.26
Analysts	Buy
Price Target	22.50 (+120.59%)
Earnings Date	Aug 28, 2026

About DXR

Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation operates as a subsidiary of Estate Of Joseph Feldschuh.

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1970
• Employees: 45
• Stock Exchange: NASDAQ
• Ticker Symbol: DXR
• Website: https://www.daxor.com

Financial Performance

In 2025, Daxor's revenue was $26,688, a decrease of -77.71% compared to the previous year's $119,714. Earnings were $9.17 million, an increase of 1609.71%.

Analyst Summary

According to 2 analysts, the average rating for DXR stock is "Buy." The 12-month stock price target is $22.5, which is an increase of 120.59% from the latest price.

Price Target

$22.5

(120.59% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Aug 13, 2026

Data Sources Report a data error